AbbVie (ABBV) Other Non-Current Liabilities (2012 - 2026)

AbbVie (ABBV) has 15 years of Other Non-Current Liabilities data on file, last reported at $34.1 billion in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $34.1 billion, up 50.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.1 billion (up 50.18% YoY), and the FY2025 annual result was $32.6 billion, up 50.32% from the prior year.
• Other Non-Current Liabilities improved to $34.1 billion in Q1 2026 per ABBV's latest filing, from $32.6 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $34.1 billion in Q1 2026 and troughed at $13.8 billion in Q1 2022.
• A 5-year average of $22.0 billion and a median of $20.2 billion in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities decreased 2.43% in 2022, then jumped 51.49% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $16.4 billion in 2022, then rose by 21.4% to $19.9 billion in 2023, then advanced by 8.93% to $21.7 billion in 2024, then jumped by 50.32% to $32.6 billion in 2025, then gained by 4.73% to $34.1 billion in 2026.
• Business Quant data shows ABBV's Other Non-Current Liabilities at $34.1 billion in Q1 2026, $32.6 billion in Q4 2025, and $31.7 billion in Q3 2025.